Angelo Gordon & Co’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Angelo Gordon & Co’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,000	Closed	-$404K	–	232
2022 Q4	$404K	Hold	40,000	–	–	0.07%	119
2022 Q3	$396K	Hold	40,000	–	–	0.07%	172
2022 Q2	$392K	Buy	+40,000	New	+$392K	0.04%	185

Angelo Gordon & Co's EBAC Position: Q1 2023 in Review

Angelo Gordon & Co sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 40,000 shares — an estimated $404K sold.

Angelo Gordon & Co first reported a position in EBAC in Q2 2022 and held it in 3 quarters. The position peaked at $404K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Angelo Gordon & Co reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Angelo Gordon & Co sold 40,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $404K.
Angelo Gordon & Co first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2022 and held it in 3 quarters.
Angelo Gordon & Co's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $404K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Angelo Gordon & Co's 13F filing for Q1 2023, filed 15 May 2023.